
NeuroPace (NPCE) Stock Forecast & Price Target
NeuroPace (NPCE) Analyst Ratings
Bulls say
NeuroPace Inc has demonstrated a significant improvement in the quality of life for patients using its RNS system, as evidenced by a meaningful increase of 3.2 points in the QOLIE-89 survey after one year of treatment. The company benefits from favorable macro trends, including a substantial increase in the number of Comprehensive Epilepsy Centers (CECs) and a 150% rise in the number of epileptologists per capita from 2012 to 2019, enhancing awareness and access to its products. Additionally, NeuroPace has reported impressive revenue growth, with a notable inflection in 2022, projecting a 75.5% increase from 2022 to 2024, which positions it favorably in the medical device sector.
Bears say
NeuroPace Inc. is facing ongoing financial challenges characterized by a consistent history of significant net losses, with no clear pathway to achieving or sustaining profitability in the near future. The company's need for additional capital may pose difficulties, leading to unfavorable funding terms that could necessitate cost-cutting measures and negatively impact its operations. Furthermore, existing financial obligations, including a restrictive term loan and uncertainty surrounding a distribution agreement, enhance the risks to its financial health and potential stock performance, compounded by challenges in market uptake and competition.
This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares